As part of the settlement an undisclosed cash consideration was paid by Ventana to Qiagen and Qiagen acknowledges that pursuant to an asset purchase agreement dated September 23, 2002, Ventana has lawfully succeeded to the rights of Beckman Coulter under the cross-license agreement originally entered into between Institut Pasteur and Life Technologies, effective April 1, 1990, and under the agreement between Institut Pasteur and Beckman Instruments (now Beckman Coulter), effective June 7, 1991.
The settlement was in reference to currently expired US Patent entitled “Human papillomavirus 44 nucleic acid hybridization probes and methods for employing the same” and US Patent entitled “Human papillomavirus 35 nucleic acid hybridization probes and methods for employing the same.”